These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 20565756)

  • 1. Co-lethality studied as an asset against viral drug escape: the HIV protease case.
    Brouillet S; Valere T; Ollivier E; Marsan L; Vanet A
    Biol Direct; 2010 Jun; 5():40. PubMed ID: 20565756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic lethals in HIV: ways to avoid drug resistance : Running title: Preventing HIV resistance.
    Petitjean M; Badel A; Veitia RA; Vanet A
    Biol Direct; 2015 Apr; 10():17. PubMed ID: 25888435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
    Lefebvre E; Schiffer CA
    AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein promiscuity: drug resistance and native functions--HIV-1 case.
    Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
    J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug Resistance Mechanism of L10F, L10F/N88S and L90M mutations in CRF01_AE HIV-1 protease: Molecular dynamics simulations and binding free energy calculations.
    Vasavi CS; Tamizhselvi R; Munusami P
    J Mol Graph Model; 2017 Aug; 75():390-402. PubMed ID: 28645089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural analyses of 2015-updated drug-resistant mutations in HIV-1 protease: an implication of protease inhibitor cross-resistance.
    Su CT; Ling WL; Lua WH; Haw YX; Gan SK
    BMC Bioinformatics; 2016 Dec; 17(Suppl 19):500. PubMed ID: 28155724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 Protease, Reverse Transcriptase, and Integrase Variation.
    Rhee SY; Sankaran K; Varghese V; Winters MA; Hurt CB; Eron JJ; Parkin N; Holmes SP; Holodniy M; Shafer RW
    J Virol; 2016 Jul; 90(13):6058-6070. PubMed ID: 27099321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of individual human immunodeficiency virus type 1 protease mutations on drug susceptibility is highly influenced by complex interactions with the background protease sequence.
    Van Marck H; Dierynck I; Kraus G; Hallenberger S; Pattery T; Muyldermans G; Geeraert L; Borozdina L; Bonesteel R; Aston C; Shaw E; Chen Q; Martinez C; Koka V; Lee J; Chi E; de Béthune MP; Hertogs K
    J Virol; 2009 Sep; 83(18):9512-20. PubMed ID: 19587054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.
    Gupta A; Jamal S; Goyal S; Jain R; Wahi D; Grover A
    BMC Bioinformatics; 2015; 16 Suppl 19(Suppl 19):S10. PubMed ID: 26695135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
    Muzammil S; Ross P; Freire E
    Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.
    Vega S; Kang LW; Velazquez-Campoy A; Kiso Y; Amzel LM; Freire E
    Proteins; 2004 May; 55(3):594-602. PubMed ID: 15103623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: possible contributions to drug resistance and a potential new target site for drugs.
    Perryman AL; Lin JH; McCammon JA
    Protein Sci; 2004 Apr; 13(4):1108-23. PubMed ID: 15044738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence of frequently transmitted drug-resistant HIV-1 variants can be explained by high viral replication capacity.
    Pingen M; Wensing AM; Fransen K; De Bel A; de Jong D; Hoepelman AI; Magiorkinis E; Paraskevis D; Lunar MM; Poljak M; Nijhuis M; Boucher CA;
    Retrovirology; 2014 Nov; 11():105. PubMed ID: 25575025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of amino acid variations in Gag and protease of HIV type 1 CRF01_AE strains on drug susceptibility of virus to protease inhibitors.
    Jinnopat P; Isarangkura-na-ayuthaya P; Utachee P; Kitagawa Y; de Silva UC; Siripanyaphinyo U; Kameoka Y; Tokunaga K; Sawanpanyalert P; Ikuta K; Auwanit W; Kameoka M
    J Acquir Immune Defic Syndr; 2009 Nov; 52(3):320-8. PubMed ID: 19727001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic profiling of substrate binding response to multidrug-resistant mutations in HIV-1 protease: Implication for combating drug resistance.
    Lv Y; Li J; Fang J; Jiao X; Yan L; Shan B
    J Mol Graph Model; 2017 Jun; 74():83-88. PubMed ID: 28371730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the drug resistance mechanism of active site, non-active site mutations and their cooperative effects in CRF01_AE HIV-1 protease: molecular dynamics simulations and free energy calculations.
    C S V; Tamizhselvi R; Munusami P
    J Biomol Struct Dyn; 2019 Jul; 37(10):2608-2626. PubMed ID: 30051758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes.
    Velazquez-Campoy A; Vega S; Freire E
    Biochemistry; 2002 Jul; 41(27):8613-9. PubMed ID: 12093278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ninety-nine is not enough: molecular characterization of inhibitor-resistant human immunodeficiency virus type 1 protease mutants with insertions in the flap region.
    Kozísek M; Sasková KG; Rezácová P; Brynda J; van Maarseveen NM; De Jong D; Boucher CA; Kagan RM; Nijhuis M; Konvalinka J
    J Virol; 2008 Jun; 82(12):5869-78. PubMed ID: 18400858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insights into a mutation-assisted lateral drug escape mechanism from the HIV-1 protease active site.
    Sadiq SK; Wan S; Coveney PV
    Biochemistry; 2007 Dec; 46(51):14865-77. PubMed ID: 18052195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.
    Nijhuis M; van Maarseveen NM; Lastere S; Schipper P; Coakley E; Glass B; Rovenska M; de Jong D; Chappey C; Goedegebuure IW; Heilek-Snyder G; Dulude D; Cammack N; Brakier-Gingras L; Konvalinka J; Parkin N; Kräusslich HG; Brun-Vezinet F; Boucher CA
    PLoS Med; 2007 Jan; 4(1):e36. PubMed ID: 17227139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.